{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:24:25Z","timestamp":1754144665341,"version":"3.41.2"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.pharep.2016.04.005","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T09:42:36Z","timestamp":1462009356000},"page":"1093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Statins, renal function and homocysteine"],"prefix":"10.1007","volume":"68","author":[{"given":"Vasilios G.","family":"Athyros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niki","family":"Katsiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri P.","family":"Mikhailidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2016.04.005_bib0070","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.pharep.2015.08.019","article-title":"Intensive statin therapy, used alone or in combination with ezetimibe, improves homocysteine level and lipid peroxidation to a similar degree in patients with coronary artery diseases","volume":"68","author":"Pytel","year":"2016","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharep.2016.04.005_bib0075","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11255-015-1180-0","article-title":"Hyperhomocysteinaemia as a potential marker of early renal function decline in middle-aged Asian people without chronic kidney disease","volume":"48","author":"Tak","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.pharep.2016.04.005_bib0080","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1517\/14656566.2015.1053464","article-title":"Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?","volume":"16","author":"Athyros","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pharep.2016.04.005_bib0085","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/jcp.2003.012989","article-title":"The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study","volume":"57","author":"Athyros","year":"2004","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.pharep.2016.04.005_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjcard.2016.01.014","article-title":"Relation between change in renal function and cardiovascular outcomes in atorvastatin-treated patients (from the Treating to New Targets [TNT] Study)","author":"Shepherd","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharep.2016.04.005_bib0095","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1185\/030079903125002315","article-title":"Statins and renal function in patients with diabetes mellitus","volume":"19","author":"Athyros","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pharep.2016.04.005_bib0100","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/ndt\/gfl538","volume":"22","author":"Athyros","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharep.2016.04.005_bib0105","doi-asserted-by":"crossref","first-page":"984","DOI":"10.5114\/aoms.2011.26610","article-title":"IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis","volume":"7","author":"Athyros","year":"2011","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.pharep.2016.04.005_bib0110","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1185\/03007990903169031","article-title":"Clinical experience with ezetimibe\/simvastatin in a Mediterranean population","volume":"25","author":"Migdalis","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pharep.2016.04.005_bib0115","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1185\/030079907X226267","article-title":"Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin","volume":"23","author":"Gazi","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pharep.2016.04.005_bib0120","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.pharep.2016.04.005_bib0125","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000110876","article-title":"Mechanisms of homocysteine-induced glomerular injury and sclerosis","volume":"28","author":"Yi","year":"2008","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.pharep.2016.04.005_bib0130","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1734-1140(09)70130-6","article-title":"Kynurenic acid protects against the homocysteine-induced impairment of endothelial cells","volume":"61","author":"Wejksza","year":"2009","journal-title":"Pharmacol Rep"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016300238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016300238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:36:29Z","timestamp":1752611789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2016.04.005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1734114016300238"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2016.04.005","relation":{},"ISSN":["1734-1140"],"issn-type":[{"type":"print","value":"1734-1140"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statins, renal function and homocysteine","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2016.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Sp. z o.o. on behalf of Institute of Pharmacology, Polish Academy of Sciences.","name":"copyright","label":"Copyright"}]}}